Stephens Inc. AR Has $12.24 Million Holdings in ResMed Inc. (NYSE:RMD)

Stephens Inc. AR decreased its holdings in shares of ResMed Inc. (NYSE:RMD) by 6.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 53,541 shares of the medical equipment provider’s stock after selling 3,918 shares during the quarter. Stephens Inc. AR’s holdings in ResMed were worth $12,244,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Cetera Investment Advisers lifted its position in shares of ResMed by 26.8% in the second quarter. Cetera Investment Advisers now owns 9,721 shares of the medical equipment provider’s stock valued at $1,861,000 after buying an additional 2,053 shares during the last quarter. Mather Group LLC. raised its stake in ResMed by 11.8% in the 3rd quarter. Mather Group LLC. now owns 701 shares of the medical equipment provider’s stock valued at $171,000 after acquiring an additional 74 shares during the period. CWM LLC lifted its holdings in ResMed by 38.4% during the 3rd quarter. CWM LLC now owns 7,899 shares of the medical equipment provider’s stock valued at $1,928,000 after purchasing an additional 2,192 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt boosted its position in ResMed by 249.7% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,224 shares of the medical equipment provider’s stock worth $299,000 after purchasing an additional 874 shares during the period. Finally, Fiduciary Financial Group LLC acquired a new position in shares of ResMed in the third quarter valued at $266,000. Institutional investors own 54.98% of the company’s stock.

ResMed Stock Down 0.1 %

RMD stock opened at $236.84 on Monday. ResMed Inc. has a 1-year low of $170.56 and a 1-year high of $263.05. The stock has a market cap of $34.78 billion, a P/E ratio of 27.96, a P/E/G ratio of 1.57 and a beta of 0.70. The stock’s fifty day simple moving average is $239.18 and its two-hundred day simple moving average is $237.59. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. Analysts expect that ResMed Inc. will post 9.44 EPS for the current year.

ResMed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 13th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.90%. ResMed’s dividend payout ratio (DPR) is presently 25.03%.

Insider Activity at ResMed

In related news, insider Justin Leong sold 6,160 shares of ResMed stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $243.09, for a total value of $1,497,434.40. Following the completion of the sale, the insider now owns 21,718 shares of the company’s stock, valued at approximately $5,279,428.62. This trade represents a 22.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total transaction of $484,220.00. Following the sale, the director now directly owns 77,218 shares in the company, valued at approximately $18,695,249.98. This trade represents a 2.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,094 shares of company stock worth $2,704,941. Insiders own 0.71% of the company’s stock.

Wall Street Analysts Forecast Growth

RMD has been the subject of several research reports. KeyCorp raised their price objective on shares of ResMed from $266.00 to $280.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Piper Sandler boosted their price target on ResMed from $252.00 to $260.00 and gave the company a “neutral” rating in a research note on Friday, January 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a report on Friday, January 31st. Stifel Nicolaus began coverage on ResMed in a report on Friday, December 13th. They set a “hold” rating and a $250.00 target price for the company. Finally, UBS Group upgraded shares of ResMed from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 31st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $244.73.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.